PanTheryx Technology

PanTheryx Technology

Medical Foods

Pipeline

Our research and experience with colostrum, eggs, and other nutrients demonstrate the potential that we can develop medical foods to manage a wide range of serious GI and other health conditions.

Medical Food for C. difficile

Diet-induced alterations in intestinal microbiota may influence colonization resistance and clostridial toxin production, providing a promising opportunity to develop nutritional interventions for C. difficile infections.

Pantheryx is developing PTX-300, a medical food, for the dietary management of C. difficile infections.

Medical Food for Inflammatory Bowel Disease

Ulcerative Colitis and Crohn’s

Crohn’s disease is associated with malnutrition in up to 85% of patients, in addition to research suggesting that there is a promising role for nutrition as a primary intervention in Crohn’s Disease.

It’s been shown that the the intestinal microbiota is involved in ulcerative colitis  pathogenesis. Nutritional support is hypothesized to improve symptoms through alterations to gut microbiota composition and activity.

Pantheryx is developing PTX-400, a medical food, for the dietary management of Ulcerative Colitis and Crohn’s.

Medical Food for Chemotherapy-Induced Diarrhea

Chemotherapy-induced diarrhea (CID)

Over 50% of cancer patients experience vomiting and diarrhea during chemotherapy. It’s been shown that dietary intake as well as specific food products influence gastrointestinal side effects of therapy. Nutritional interventions offer a promising approach to address chemotherapy-induced gastrointestinal symptoms and enhance quality of life.

Pantheryx is developing PTX-500, a medical food, for the dietary management of CID.